How Many 'New' entities Can Be Created from One Active Substance? The Case of Cyclosporin A

Alexandr Jegorov; Michal Husak; Bohumil Kratochvil; Ivana Cisarova

首页> 外文期刊>Crystal growth & design >How Many 'New' entities Can Be Created from One Active Substance? The Case of Cyclosporin A

【24h】

How Many 'New' entities Can Be Created from One Active Substance? The Case of Cyclosporin A

机译：一个活性物质可以创建多少个“新”实体？环孢菌素A的情况

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The existence of various crystalline forms of active substances, which can potentially differ in their pharmacokinetic profile, bioavailability or stability, creates the possibility of extending the patent protection of "old" substances utilizing the structures of new crystalline forms. Using cyclosporin A as an example, this report points to the fact that even with relatively small molecules, having about 60 non-hydrogen atoms, the number of "new" entities that can be generated can be at times nearly infinite.

机译：活性物质的各种晶形的存在，可能在其药代动力学特征，生物利用度或稳定性方面可能存在差异，从而有可能利用新晶形的结构扩展对“旧”物质的专利保护。以环孢菌素A为例，该报告指出了这样一个事实，即使对于具有约60个非氢原子的相对较小的分子，可以产生的“新”实体的数量有时也可以接近无限。

著录项

来源
《Crystal growth & design》 |2003年第4期|共4页
作者
Alexandr Jegorov; Michal Husak; Bohumil Kratochvil; Ivana Cisarova;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类晶体学;
关键词

相似文献

外文文献
中文文献
专利

1. How Many "New" entities Can Be Created from One Active Substance? The Case of Cyclosporin A [J] . Alexandr Jegorov, Michal Husak, Bohumil Kratochvil, Crystal growth & design . 2003,第4期

机译：一个活性物质可以创建多少个“新”实体？环孢菌素A的情况
2. A method of creating a cell monolayer based on organotypic culture for screening of physiologically active substances [J] . KhavinsonV.K., LinkovaN.S., PronyaevaV.E., Bulletin of experimental biology and medicine . 2012,第5期

机译：一种基于有机型培养的细胞单层的筛选方法，用于筛选生理活性物质
3. Exchange Interaction of Quantum Entities as Interaction of Spin Vortices Created by the Quantum Entities in the Physical Vacuum [J] . Liudmila B. Boldyreva International Journal of Physics . 2018,第3期

机译：量子实体的交换相互作用作为物理真空中量子实体产生的自旋涡旋的相互作用。
4. PharmaCoNER: Pharmacological Substances, Compounds and proteins Named Entity Recognition track [C] . Aitor Gonzalez-Agirre, Montserrat Marimon, Ander Intxaurrondo, Workshop on bioNLP open shared tasks . 2019

机译：PharmaCoNER：药理物质，化合物和蛋白质命名为实体识别轨迹
5. Realizing a vision: Experiences of individuals who created a concrete and enduring entity. [D] . Hinds, Diane Jean Madison. 2007

机译：实现愿景：创建具体而持久的实体的个人的经验。
6. Guidance of EFSA on risk assessments for active substances of plant protection products that have stereoisomers as components or impurities and for transformation products of active substances that may have stereoisomers [O] . European Food Safety Authority (EFSA), László Bura, Anja Friel, 2019

机译：EFSA关于以立体异构体为成分或杂质的植物保护产品活性物质以及可能具有立体异构体的活性物质转化产物风险评估的指南
7. Bootstrapping Named Entity Annotation by Means of Active Machine Learning: A Method for Creating Corpora [O] . Olsson Fredrik 2008

机译：通过主动机器学习自举命名实体注释：一种创建语料库的方法

How Many 'New' entities Can Be Created from One Active Substance? The Case of Cyclosporin A

摘要

著录项

相似文献

相关主题

期刊订阅